Laboratory of Veterinary Small Animal Internal Medicine, Department of Veterinary Medicine, Faculty of Agriculture, Iwate University, Morioka, Iwate, Japan.
Central Research Institute, Maruha Nichiro Corporation, Tsukuba, Ibaraki, Japan.
J Feline Med Surg. 2022 Dec;24(12):e505-e512. doi: 10.1177/1098612X221136815. Epub 2022 Nov 16.
Lipids containing n-3 fatty acids have been reported to have protective effects on renal function, with docosahexaenoic acid (DHA) expected to be particularly effective. However, no reports have demonstrated the renoprotective effects of DHA-enriched lipids in cats with chronic kidney disease (CKD). Therefore, the aim of this pilot study was to examine the renoprotective effects of DHA-enriched fish oil in cats.
Five healthy cats and five cats with early non-azotaemic CKD due to autosomal dominant polycystic kidney disease (PKD) were orally administered DHA-enriched fish oil in liquid form (250 or 500 mg/kg body weight [BW] and 250 mg/kg BW of DHA, respectively) for 28 days. Inappropriately dilute urine and markedly increased urinary -acetyl-d-glucosamine (NAG) index were detected in cats with PKD before DHA-enriched fish oil administration. Changes in the fatty acid composition ratio in the blood of all 10 cats were assessed after orally administering 250 mg/kg of DHA.
Post-administration, no adverse clinical effects were observed, and blood and urine tests were within the reference intervals in healthy cats. Cats with PKD showed significantly decreased serum symmetric dimethylarginine (SDMA), urine protein:creatinine ratio (UPC) and urinary NAG index at post-administration. Furthermore, oral administration of DHA-enriched fish oils significantly decreased the blood concentration ratio of arachidonic acid (AA) in cats with PKD post-administration. Furthermore, the concentration ratio of DHA in the blood significantly increased in both healthy cats and cats with PKD, and the DHA:AA ratio also increased.
Oral administration of DHA-enriched fish oils for 28 days significantly decreased blood AA levels and significantly increased DHA concentration and DHA:AA ratios in cats with PKD, and improved the SDMA, UPC and urinary NAG index, suggesting its potential for renoprotective effects in cats with early non-azotaemic CKD due to PKD.
含有 n-3 脂肪酸的脂质已被报道对肾功能具有保护作用，二十二碳六烯酸（DHA）的作用预计尤为显著。然而，目前尚无报告显示富含 DHA 的脂质对患有慢性肾病（CKD）的猫具有肾脏保护作用。因此，本初步研究旨在探讨富含 DHA 的鱼油对猫肾脏的保护作用。
将 5 只健康猫和 5 只因常染色体显性多囊肾病（PKD）而患有早期非氮质血症 CKD 的猫以口服方式给予富含 DHA 的鱼油（分别以 250 或 500mg/kg 体重和 250mg/kg 体重给予 DHA），为期 28 天。在给予富含 DHA 的鱼油之前，PKD 猫的尿液被检测出不适当稀释且尿 -N-乙酰-β-D-氨基葡萄糖苷（NAG）指数显著增加。所有 10 只猫在口服 250mg/kg 的 DHA 后，评估其血液中脂肪酸组成比例的变化。
给药后，健康猫未观察到不良反应，血液和尿液检查均处于参考区间内。PKD 猫在给药后，血清对称二甲基精氨酸（SDMA）、尿蛋白/肌酐比（UPC）和尿 NAG 指数显著降低。此外，口服富含 DHA 的鱼油可显著降低 PKD 猫给药后的血液花生四烯酸（AA）浓度比。此外，富含 DHA 的鱼油口服给药后，健康猫和 PKD 猫的血液中 DHA 浓度比均显著增加，且 DHA:AA 比值也增加。
口服富含 DHA 的鱼油 28 天可显著降低 PKD 猫的血液 AA 水平，并显著增加 DHA 浓度和 DHA:AA 比值，改善 SDMA、UPC 和尿 NAG 指数，提示其在患有因 PKD 引起的早期非氮质血症 CKD 的猫中具有肾脏保护作用的潜力。
